Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate clinical efficacy, toxicity and long term results with Blinatumomab and Tyrosine Kinase Inhibitors Combination in Relapsed/Refractory Acute Lymphoblastic Leukemia

Trial Profile

To evaluate clinical efficacy, toxicity and long term results with Blinatumomab and Tyrosine Kinase Inhibitors Combination in Relapsed/Refractory Acute Lymphoblastic Leukemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top